Skip to Content
Are you living with NSCLC? Learn your prognosis here >>

Medications for Lymphangioleiomyomatosis

Other names: LAM; Pulmonary Lymphangioleiomyomatosis

What is Lymphangioleiomyomatosis: Lymphangioleiomyomatosis is a rare lung disease characterized by proliferation of normal smooth muscle-like cells (LAM cells) in the lungs, causing cysts which lead to breathing problems. It typically affects women of childbearing age.

Compare drugs associated with Lymphangioleiomyomatosis

The following list of medications are in some way related to, or used in the treatment of this condition.

Drug name Rx / OTC Pregnancy CSA Alcohol Reviews Rating Popularity
Rapamune Rx C N Add review Add

Generic name: sirolimus systemic

Drug class: mTOR inhibitors, selective immunosuppressants

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

 
sirolimus Rx C N Add review Add

Generic name: sirolimus systemic

Brand name:  Rapamune

Drug class: mTOR inhibitors, selective immunosuppressants

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information

 
Showing all

Legend

Off Label This medication may not be approved by the FDA for the treatment of this condition.
Prescription Only / Over the Counter
Rx Prescription Only
OTC Over the Counter
Rx/OTC Prescription or Over the Counter
Pregnancy
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act Schedule
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Browse Drugs by Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Hide